Strategic partnership Leverage existing collaboration history with Novartis and recent CRO partnerships to position Conatus as a partner-of-choice for liver disease programs, offering access to a broad network, potential co-development routes, and accelerated engagement with biopharma stakeholders.

Clinical differentiation Emphasize emricasan as a first-in-class pan-caspase inhibitor with biomarkers linked to inflammation and apoptosis, highlighting potential applicability across multiple liver disease etiologies and stages to unlock cross-indication pitching with licensees and investigators.

Clinical pipeline expansion Target discovery and preclinical collaboration opportunities with hepatology CROs and regenerative medicine players to expand the emricasan program or combine with Histogen’s tissue regeneration capabilities through potential strategic fit or acquisition conversations.

Market timing Capitalize on a modest revenue footprint and strategic funding to pursue value-building partnerships, licensing deals, or milestone-based collaborations with mid-to-large biotechs seeking late-stage liver disease assets or platform-stage inflammation/apoptosis inhibitors.

Competitive positioning Differentiate by showcasing validated biomarker endpoints and demonstrable reductions in inflammatory/apoptotic markers across diverse liver disease etiologies, positioning for discussions with larger pharma players seeking a versatile liver disease asset with global development potential.